Ketoconazole (KTZ) is commonly used by pharmaceutical companies to characterize the worst-case drug interaction for CYP3A substrates under development. Doses of 200 mg and 400 mg of KTZ have been used in human drug interaction studies with midazolam (MDZ). However, large variations in the magnitude of interaction are observed. No single study has compared the inhibitory effect of 200 mg vs. 400 mg of KTZ. Thus, it is unclear whether the worst-case drug interaction study requires 400 mg of KTZ or if a 200 mg dose would suffice. CYP3A5 genotype may in part explain individual variability in metabolism and drug-drug interactions exhibited by CYP3A substrates due to its polymorphic and racially diverse expression. Twenty-four healthy volunteers ...
Antifungal drug ketoconazole causes severe drug-drug interactions by influencing gene expression and...
textabstractPurpose: Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the...
Thesis (Ph. D.)--University of Washington, 2001Cytochrome P450 (CYP) 3A4 and 3A5 constitute the domi...
Ketoconazole is a potent CYP3A inhibitor used to assess the con-tribution of CYP3A to drug clearance...
We verified a physiologically‐based pharmacokinetic (PBPK) model to predict cytochrome P450 3A4/5‐me...
Whereas ketoconazole is often used to study the worst-case sce-nario for clinical pharmacokinetic dr...
The allosteric effect of fluconazole (effector) on the formation of 1’-hydroxymidazolam (1’-OH-MDZ) ...
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s s...
A novel in vitro model was recently developed in our laboratories for the prediction of magnitude of...
The clinical impact of drug-drug interactions based on time-dependent inhibition of cytochrome P450 ...
is an orally bioavailable and potent dual antagonist of the D-pros-tanoid and chemoattractant recept...
PURPOSE: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P45...
The prediction of the extent of drug-drug interactions (DDIs) between the mechanism-based inhibitors...
The complexity of in vitro kinetic phenomena observed for CYP3A4 substrates (homo- or heterotropic c...
Abstract Objective: The aim of this crossover human ale volunteer study was to investigate the uti...
Antifungal drug ketoconazole causes severe drug-drug interactions by influencing gene expression and...
textabstractPurpose: Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the...
Thesis (Ph. D.)--University of Washington, 2001Cytochrome P450 (CYP) 3A4 and 3A5 constitute the domi...
Ketoconazole is a potent CYP3A inhibitor used to assess the con-tribution of CYP3A to drug clearance...
We verified a physiologically‐based pharmacokinetic (PBPK) model to predict cytochrome P450 3A4/5‐me...
Whereas ketoconazole is often used to study the worst-case sce-nario for clinical pharmacokinetic dr...
The allosteric effect of fluconazole (effector) on the formation of 1’-hydroxymidazolam (1’-OH-MDZ) ...
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s s...
A novel in vitro model was recently developed in our laboratories for the prediction of magnitude of...
The clinical impact of drug-drug interactions based on time-dependent inhibition of cytochrome P450 ...
is an orally bioavailable and potent dual antagonist of the D-pros-tanoid and chemoattractant recept...
PURPOSE: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P45...
The prediction of the extent of drug-drug interactions (DDIs) between the mechanism-based inhibitors...
The complexity of in vitro kinetic phenomena observed for CYP3A4 substrates (homo- or heterotropic c...
Abstract Objective: The aim of this crossover human ale volunteer study was to investigate the uti...
Antifungal drug ketoconazole causes severe drug-drug interactions by influencing gene expression and...
textabstractPurpose: Panobinostat is partly metabolized by CYP3A4 in vitro. This study evaluated the...
Thesis (Ph. D.)--University of Washington, 2001Cytochrome P450 (CYP) 3A4 and 3A5 constitute the domi...